Cylex, Inc.'s Immune Function Test, ImmuKnow(R), Identifies Optimal Immune Status For Post-Transplant Therapy

COLUMBIA, Md., Sept. 12 /PRNewswire/ -- Cylex Incorporated, a life sciences company and leader in immune function testing, today announced study results on the effectiveness of ImmuKnow® in minimizing the risk of infection and rejection in post-transplant patients. Testing with ImmuKnow enables doctors to tailor immunosuppressant drug regimens to prevent organ rejection while avoiding infection.
MORE ON THIS TOPIC